12 results
To assess safety, tolerability and pharmacokinetics of a single subcutaneous administration of HPV-NIRD1.
To investigate the correlation of pharmacokinetic parameters of anidulafungin with markers for disease severity and plasma protein levels.
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin given once in every 2 days (q48h) or once in every 3 days (q72h) to patients undergoing an allogeneic haematopoietic stem cell transplant…
The purpose of this study is to understand if a new treatment for prostate cancer (niraparib) added to a standard treatment (abiraterone acetate plus prednisone) will work better than the standard treatment alone.Cohort 3: the purpose is to evaluate…
The primary objective of this trial is as follows:• To determine the pharmacokinetics of anidulafungin administered to obese patients with a BMI >= 40 kg/m2. The secondary objective of this trial is as follows:• To simulate pharmacokinetics…
Aim of the present study is to investigate if a combination of a radioactive and fluorescent tracer can increase the sensitivity and specificity of the SLNM technique in colon and rectal cancer by utilizing the radioactive component for preoperative…
To determine which advanced image enhanced modality is the most feasible for the detection of endometriosis lesions, with respect to the specificity and sensitivity of the investigated modalities. To determine which imaging modality reveals more…
Aim of the study is to develop an intraoperative technique for SLN mapping in colon cancer which is suitably in daily practice in colon surgery in an average hospital setting.
Primary Objective:-Evaluate tumour detection sensitivity and specificity with the following image enhancement modalities:1 *narrow-band imaging*, (NBI)2 *near-infrared indocyanin green imaging*, (ICG)3 *5-aminolevulinic acid fluorescent imaging*, (5…
Objectives: The primary objectives of this study are: • Part 1 (dose-escalation): To evaluate the safety of SYD985 in combination with niraparib to determine the maximum tolerated dose (MTD) and recommended combination dose regimen for expansion (…
Primary objective:- To assess the efficacy of niraparib in subjects with measurable mCRPC and who have either biallelic DNA-repair anomalies in BRCA (BRCA 1 and BRCA 2 or germline BRCA. Secondary objectives:- To assess the efficacy of niraparib in…
The primary objective of this study is to determine the immune-activating capacity of treatment with pembrolizumab and carboplatin/paclitaxel in the neo-adjuvant setting of primary stage IV ovarian cancer as measured by the alteration in magnitude…